Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Geron (0IV3) Share Price & Analysis

0IV3 Stock Chart & Stats

$0.88-$0.06(-5.89%)
At close: 4:30 PM GMT
$1$1.25$1.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$0.87 - $0.95
52-Week Range
$0.85 - $2.00
Previous Close
$0.93
Volume
48.57K
Average Volume (3M)
70.22K
Market Cap
$574.63M
Enterprise Value
$807.52M
Total Cash (Recent Filing)
$300.85M
Total Debt (Recent Filing)
$122.14M
Price to Earnings (P/E)
―
Beta
1.24
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
-0.01
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

RYTELO Revenue And Adoption Growth

Growing RYTELO revenue alongside expansion in prescribing accounts indicates increasing commercial adoption in the lower-risk MDS market. Continued demand growth and management’s expectation of reaching the mid- to high-end of 2026 guidance support a developing revenue base over the next several quarters.

Improving Operating Leverage

Revenue growth materially outpacing operating-expense growth demonstrates improving operating leverage as the commercial franchise scales. If this relationship persists, it can reduce the cost burden of expansion and provide a clearer path toward improved operating profitability without requiring equivalent increases in spending.

Stronger Capital Structure

Very low debt relative to equity gives Geron greater financial flexibility than in the prior year, while its cash and securities provide resources for commercial investment and clinical programs. This stronger capital structure can help support execution through the product’s growth phase and reduce near-term financing pressure.

Bears Say

Persistent Cash Burn

Deeply negative operating and free cash flow show that the business is not yet self-funding despite commercial revenue growth. Continued cash burn can consume financial resources, increase reliance on external funding or balance-sheet reserves, and constrain the company’s ability to invest across commercial and clinical priorities.

Ongoing Net Losses

Geron remains unprofitable even as revenue scales, indicating that product growth has not yet covered development, commercial, and corporate costs. Sustained net losses can delay internally generated capital formation and leave future profitability dependent on continued adoption, expense control, and successful operating leverage.

Myelofibrosis Program Setback

Discontinuing IMpactMF removes a major clinical opportunity from the development portfolio after the study was judged unlikely to meet its primary endpoint. The setback narrows imetelstat’s potential beyond lower-risk MDS, increases reliance on RYTELO execution, and weakens diversification within the pipeline.

Geron News

0IV3 FAQ

What was Geron’s price range in the past 12 months?
Geron lowest share price was $0.85 and its highest was $2.00 in the past 12 months.
What is Geron’s market cap?
Geron’s market cap is $574.63M.
When is Geron’s upcoming earnings report date?
Geron’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is in 2 days.
How were Geron’s earnings last quarter?
Geron released its earnings results on Aug 05, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.011.
Is Geron overvalued?
According to Wall Street analysts Geron’s price is currently Undervalued.
Does Geron pay dividends?
Geron pays a Notavailable dividend of $0.285 which represents an annual dividend yield of ―. See more information on Geron dividends here
What is Geron’s EPS estimate?
Geron’s EPS estimate is -0.01.
How many shares outstanding does Geron have?
Geron has 642,473,400 shares outstanding.
What happened to Geron’s price movement after its last earnings report?
Geron reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 16.045%.
Which hedge fund is a major shareholder of Geron?
Hedge funds hold Geron shares: the largest hedge-fund position in Geron is 1,909,136,573 shares, and hedge funds decreased their holdings by 19.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology